Published in Gene Therapy Weekly, March 23rd, 2000
Antisense oligonucleotides are a new class of pharmaceuticals that act by attenuating the actual production of disease-related proteins. EpiGenesis has pioneered a new form of antisense oligonucleotides known as RASONs, designed for direct application to the lung via aerosol inhalation. In this manner, a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.